News

Eli Lilly to buy privately held SiteOne in deal worth up to $1 billion
Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...
Lilly snags Peninsula non-opioid pain drug company for up to $1 billion
Eli Lilly acquires SiteOne Therapeutics for up to $1B, signaling potential uptick in Big Pharma deals and focus on non-opioid ...
Eli Lilly Targets Pain Management Opportunity with SiteOne Therapeutics Acquisition
Eli Lilly and Company (NYSE:LLY) is expanding its footprint into the non-opioid pain management market in pursuit of growth ...
BioPharma Dive4h
Lilly to buy pain drug developer SiteOne, challenging Vertex
The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.
Indianapolis Business Journal6h
Lilly seeks to expand pain pipeline with $1B acquisition
SiteOne Therapeutics is developing a non-opioid therapy that targets sodium ion channels in the human body to treat pain and ...
Stocktwits on MSN6h
Eli Lilly To Acquire SiteOne Therapeutics For Up To $1B To Advance Pain Management Pipeline: But Retail’s Unconvinced
Eli Lilly and Company (LLY) said on Tuesday that it would acquire California-based private biotechnology company SiteOne ...
Here's How the Pharmaceutical Import Tariffs Could Affect Eli Lilly
The U.S. imports more pharmaceutical products from Ireland than from any other country -- nearly $50 billion last year. It won't be surprising if the Trump administration especially targets those ...